Rubius Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Rubius Therapeutics

09/11/2022 15:38

* Rubius Therapeutics Inc  RUBY.OQ  reported a quarterly
adjusted
loss of 36 cents​​ per share for the quarter ended in September.
The mean expectation of three analysts for the quarter was for a
loss of 39 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Rubius Therapeutics Inc's reported EPS for the quarter was
a
loss of 70 cents​.
    * The mean earnings estimate of analysts had risen by
about 21.1%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Rubius Therapeutics Inc shares had fallen by 46.7% this
quarter and lost 97.6% so far this year.
    * The company reported a quarterly loss of $62.87 million.
    * Wall Street's median 12-month price target for Rubius
Therapeutics Inc is $10.50 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
9 at 03:37 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.39          -0.36          Beat
 Jun. 30 2022      -0.53          -0.49          Beat
 Mar. 31 2022      -0.58          -0.58          Met
 Dec. 31 2021      -0.59          -0.61          Missed